Voyager Therapeutics Announces Licensing Agreement With Pfizer To Develop Gene Therapies

Voyager Therapeutics, Inc. (VYGR) on Wednesday announced a licensing agreement with Pfizer for Voyager's TRACER AAV Capsids to develop gene therapies for certain neurologic and cardiovascular diseases.

The deal gives Pfizer the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager's TRACER ((Tropism Redirection of AAV by Cell-type-specific Expression of RNA)) platform, and to license capsids for exclusive use in Pfizer's development of AAV gene therapies incorporating two undisclosed transgenes.

Voyager will receive $30 million as upfront payment and is eligible for up to $20 million in exercise fees for two options, exercisable by Pfizer within 12 months of signing.

In addition, Voyager is entitled to get up to $580 million on reaching certain targets associated with licensed products incorporating the two undisclosed Pfizer transgenes together with a Voyager licensed capsid. Voyager is also eligible to receive mid- to high-single-digit tiered royalties based on net sales of Pfizer's products incorporating the licensed capsids.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT